Kazia Therapeutics Stock (NASDAQ:KZIA)
Previous Close
$5.08
52W Range
$1.90 - $15.80
50D Avg
$4.60
200D Avg
$3.61
Market Cap
$16.91M
Avg Vol (3M)
$145.77K
Beta
2.08
Div Yield
-
KZIA Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Performance
KZIA Financial Summary
Peer Comparison
| Ticker | Company |
|---|---|
| NRIX | Nurix Therapeutics, Inc. |
| SEER | Seer, Inc. |
| ACHL | Achilles Therapeutics plc |
| MREO | Mereo BioPharma Group plc |
| NLSP | NLS Pharmaceutics AG |
| OKYO | OKYO Pharma Limited |
| DAWN | Day One Biopharmaceuticals, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| QSI | Quantum-Si incorporated |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| OCUL | Ocular Therapeutix, Inc. |
| SLS | SELLAS Life Sciences Group, Inc. |
| HCWB | HCW Biologics Inc. |
| ASMB | Assembly Biosciences, Inc. |
| MNOV | MediciNova, Inc. |
| RNXT | RenovoRx, Inc. |
| CADL | Candel Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ABIO | ARCA biopharma, Inc. |